{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:33:22Z","timestamp":1787502802126,"version":"build-2736575974"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:title>Graphical Abstract<\/jats:title>","DOI":"10.3389\/fphar.2024.1352224","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T10:17:52Z","timestamp":1715336272000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4\/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Francisco Cezar Aquino de","family":"Moraes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R. M.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitor Kendi Tsuchiya","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estella Aparecida De","family":"Laia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Stecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rommel Mario Rodr\u00edguez","family":"Burbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"B1","unstructured":"Chapter 13: assessing risk of bias due to missing results in a synthesis2023"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1758835919833867","DOI":"10.1177\/1758835919833867","article-title":"Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication","volume":"11","author":"Bellet","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1080\/03007995.2017.1348344","article-title":"A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer","volume":"33","author":"Bilgin","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/clpt.2012.73","article-title":"Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?","volume":"92","author":"Budha","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00228-022-03435-7","article-title":"The effect of concomitant use of proton pump inhibitors with CDK 4\/6 inhibitors on survival in metastatic breast cancer","volume":"79","author":"\u00c7a\u011flayan","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"33770","DOI":"10.1039\/d3ra05672d","article-title":"Exploring cyclin-dependent kinase inhibitors: a comprehensive study in search of CDK-6 inhibitors using a pharmacophore modelling and dynamics approach","volume":"13","author":"Chagaleti","year":"2023","journal-title":"RSC Adv."},{"key":"B7","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.21873\/anticanres.16732","article-title":"Mechanism of CDK4\/6 inhibitor resistance in hormone receptor-positive breast cancer and alternative treatment strategies","volume":"43","author":"Chang","year":"2023","journal-title":"Anticancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/jamaoncol.2016.3358","article-title":"Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013\/LOGiC randomized clinical trial","volume":"3","author":"Chu","year":"2017","journal-title":"JAMA Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"PD13","DOI":"10.1158\/1538-7445.SABCS22-PD13-10","article-title":"Abstract PD13-10: PD13-10 impact of proton pump inhibitors (PPI) on palbociclib (PAL) outcomes in hormone receptor-positive, HER2-negative advanced breast cancer (HR+\/HER2- ABC): exploratory analysis of the PARSIFAL trial","volume":"83","author":"Cosimo","year":"2023","journal-title":"Cancer Res."},{"key":"bib63","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101431","article-title":"243P Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in metastatic breast cancer patients","volume":"8","author":"Criado","year":"2023","journal-title":"ESMO Open"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.2147\/CMAR.S300869","article-title":"Prognostic factors in hormone receptor-positive\/human epidermal growth factor receptor 2-negative (HR+\/HER2\u2013) advanced breast cancer: a systematic literature review","volume":"13","author":"Cuy\u00fan Carter","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.breast.2022.10.005","article-title":"Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib","volume":"66","author":"Del Re","year":"2022","journal-title":"Breast"},{"key":"B12","doi-asserted-by":"publisher","first-page":"100231","DOI":"10.1016\/j.esmoop.2021.100231","article-title":"Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients","volume":"6","author":"Del Re","year":"2021","journal-title":"ESMO Open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin. Trials"},{"key":"B14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12885-022-09624-y","article-title":"Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study","volume":"22","author":"Eser","year":"2022","journal-title":"BMC Cancer"},{"key":"B16","unstructured":"OncologyPRO2023"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1080\/0284186X.2023.2254475","article-title":"Current treatment landscape of HR+\/HER2-advanced breast cancer in the Nordics: a modified Delphi study","volume":"62","author":"Geisler","year":"2023","journal-title":"Acta Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S1470-2045(22)00015-8","article-title":"Progression-free survival: it is time for a new name","volume":"23","author":"Gyawali","year":"2022","journal-title":"Lancet Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","article-title":"Targeting CDK4\/6 in patients with cancer","volume":"45","author":"Hamilton","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1177\/10600280211059040","article-title":"Are proton pump inhibitors more effective than histamine-2-receptor antagonists for stress ulcer prophylaxis in critically ill patients? A systematic review and meta-analysis of cohort studies","volume":"56","author":"He","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.lungcan.2013.06.008","article-title":"An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib","volume":"82","author":"Hilton","year":"2013","journal-title":"Lung Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/87551225231205153","article-title":"Updated review article: cyclin-dependent kinase 4\/6 inhibitor impact, FDA approval, and resistance pathways","volume":"39","author":"Hunter","year":"2023","journal-title":"J. Pharm. Technol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut"},{"key":"B25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.3390\/curroncol30060411","article-title":"HR+\/HER2\u2013 advanced breast cancer treatment in the first-line setting: expert review","volume":"30","author":"Jerzak","year":"2023","journal-title":"Curr. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/s41588-023-01507-7","article-title":"Molecular classification of hormone receptor-positive HER2-negative breast cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Nat. Genet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"00211","DOI":"10.1016\/j.tcb.2023.10.007","article-title":"Cancer takes many paths through G1\/S","author":"Knudsen","year":"2023","journal-title":"Trends Cell Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"85542","DOI":"10.18632\/oncotarget.13458","article-title":"EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction","volume":"7","author":"Kumarakulasinghe","year":"2016","journal-title":"Oncotarget"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e2324852","DOI":"10.1001\/jamanetworkopen.2023.24852","article-title":"Concomitant use of proton pump inhibitors and palbociclib among patients with breast cancer","volume":"6","author":"Lee","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"B31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"B32","article-title":"Quality improvement interventions to address health disparities: closing the quality gap - revisiting the state of the science","volume-title":"Database of abstracts of reviews of effects (DARE): quality-assessed reviews","author":"McPheeters","year":"2012"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.3390\/cancers14194721","article-title":"Effect of concomitant proton pump inhibitors with pazopanib on cancer patients: a retrospective analysis","volume":"14","author":"Moreau-Bachelard","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/clpt.2012.182","article-title":"Drug interactions produced by proton pump inhibitors: not simply a pH effect","volume":"93","author":"Mullin","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.critrevonc.2017.01.014","article-title":"Proton Pump Inhibitors in cancer patients: how useful they are? A review of the most common indications for their use","volume":"111","author":"Numico","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3390\/medicina59030557","article-title":"Does proton pump inhibitors decrease the efficacy of palbociclib and ribociclib in patients with metastatic breast cancer?","volume":"59","author":"Odabas","year":"2023","journal-title":"Med. Kaunas."},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.36255\/exon-publications-breast-cancer-subtypes","article-title":"Subtypes of breast cancer","volume-title":"Breast cancer","author":"Orrantia-Borunda","year":"2022"},{"key":"B38","unstructured":"Ottawa hospital research Institute2023"},{"key":"B39","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.13345\/j.cjb.220478","article-title":"Advances of the regulatory mechanism of cyclin, cyclin-dependent kinases and related kinase inhibitors in cell cycle progression","volume":"39","author":"Pan","year":"2023","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"B41","unstructured":"LiverTox: clinical and research information on drug-induced liver injury (bethesda (MD): national Institute of diabetes and digestive and kidney diseases)2012"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e2113739","DOI":"10.1001\/jamanetworkopen.2021.13739","article-title":"Prevalence of proton pump inhibitor use among patients with cancer","volume":"4","author":"Raoul","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B43","doi-asserted-by":"publisher","first-page":"100880","DOI":"10.1016\/j.esmoop.2023.100880","article-title":"Drug-drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure","volume":"8","author":"Raoul","year":"2023","journal-title":"ESMO Open"},{"key":"B44","doi-asserted-by":"publisher","first-page":"ed88","DOI":"10.3332\/ecancer.2019.ed88","article-title":"Drug interactions and oncological outcomes: a hidden adversary","volume":"13","author":"Riechelmann","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.2165\/00003495-200363240-00004","article-title":"Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know","volume":"63","author":"Robinson","year":"2003","journal-title":"Drugs"},{"key":"B46","doi-asserted-by":"publisher","first-page":"6350","DOI":"10.3390\/ijms21176350","article-title":"CDK4\/6 inhibitors in breast cancer treatment: potential interactions with drug, gene, and pathophysiological conditions","volume":"21","author":"Roncato","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/cpt.940","article-title":"Ribociclib bioavailability is not affected by gastric pH changes or food intake: in silico and clinical evaluations","volume":"104","author":"Samant","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.clbc.2023.05.009","article-title":"Effect of concurrent proton pump inhibitors with palbociclib tablets for metastatic breast cancer","volume":"23","author":"Schieber","year":"2023","journal-title":"Clin. Breast Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.bcp.2005.11.030","article-title":"Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo","volume":"71","author":"Shin","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of proton pump inhibitors","volume":"10","author":"Shin","year":"2008","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B51","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1021\/mp400403s","article-title":"Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development","volume":"10","author":"Smelick","year":"2013","journal-title":"Mol. Pharm."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3390\/pharmaceutics14102043","article-title":"Formulation of dosage forms with proton pump inhibitors: state of the art, challenges and future perspectives","volume":"14","author":"Srebro","year":"2022","journal-title":"Pharmaceutics"},{"key":"B53","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/cpdd.356","article-title":"Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food intake conditions","volume":"6","author":"Sun","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B54","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1572-0241.2007.01106.x","article-title":"The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use","volume":"102","author":"Targownik","year":"2007","journal-title":"Official J. Am. Coll. Gastroenterology | ACG"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2022-12-2","article-title":"HR+\/HER2\u2212 de novo metastatic breast cancer: a true peculiar entity?","volume":"12","author":"Torrisi","year":"2023","journal-title":"Drugs Context"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41698-023-00407-7","article-title":"Targeting CDK1 in cancer: mechanisms and implications","volume":"7","author":"Wang","year":"","journal-title":"NPJ Precis. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"110848","DOI":"10.1016\/j.intimp.2023.110848","article-title":"Mechanism of M2 type macrophage-derived extracellular vesicles regulating PD-L1 expression via the MISP\/IQGAP1 axis in hepatocellular carcinoma immunotherapy resistance","volume":"124","author":"Wang","year":"","journal-title":"Int. Immunopharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update","volume":"37","author":"Wedemeyer","year":"2014","journal-title":"Drug Saf."},{"key":"B60","doi-asserted-by":"publisher","first-page":"41021","DOI":"10.1038\/srep41021","article-title":"Effectiveness and tolerability of different recommended doses of PPIs and H2RAs in GERD: network meta-analysis and GRADE system","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12890-023-02754-4","article-title":"PPIs therapy has a negative impact on the clinical outcomes of advanced SCLC patients treated with PD-L1 inhibitors","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Pulm. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1352224\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T10:17:59Z","timestamp":1715336279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1352224\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":62,"alternative-id":["10.3389\/fphar.2024.1352224"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1352224","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"article-number":"1352224"}}